Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10282302 | 1.00 | MELK (0.67) | MELKIRAK4 | |
| SCHEMBL27907327 | 0.90 | MELK (0.59) | MELKIRAK4 | |
| SCHEMBL15197562 | 0.90 | MELK (0.56) | MELK | |
| SCHEMBL27907328 | 0.90 | MELK (0.59) | MELKIRAK4 | |
| SCHEMBL27925429 | 0.90 | MELK (0.59) | MELKIRAK4 | |
| SCHEMBL530753 | 0.89 | MELK (0.72) | MELKIRAK4 | |
| SCHEMBL530754 | 0.89 | MELK (0.72) | MELKIRAK4 | |
| SCHEMBL531437 | 0.88 | MELK (0.69) | MELKIRAK4 | |
| SCHEMBL15191172 | 0.88 | MELK (0.69) | MELKIRAK4 | |
| SCHEMBL27907388 | 0.88 | MELK (0.60) | MELKIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2597955-B1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE INC (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-9120749-B2 | Quinoline derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-09-01 | — | — | US | disclosed |
| US-20130217671-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-08-22 | — | — | US | disclosed |
| EP-2597955-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | OncoTherapy Science, Inc. (JP) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012016082-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217671-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | MELK, NADK, NEK1 | MELK 1/4885IRAK4 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.